CAS 1370651-20-9

Formula: C26H27Cl2FN6O3

InChI: InChI=1S/C26H27Cl2FN6O3/c1-13-11-35(12-14(2)31-13)26(37)16-4-6-17(7-5-16)32-25(36)20-10-21(24(30)34-33-20)38-15(3)22-18(27)8-9-19(29)23(22)28/h4-10,13-15,31H,11-12H2,1-3H3,(H2,30,34)(H,32,36)/t13-,14+,15-/m1/s1

InChI key: GLYMPHUVMRFTFV-QLFBSQMISA-N

SMILES: C[C@@H]1CN(C[C@@H](N1)C)C(=O)C2=CC=C(C=C2)NC(=O)C3=NN=C(C(=C3)O[C@H](C)C4=C(C=CC(=C4Cl)F)Cl)N

Ensartinib

CAS: 1370651-20-9

Ensartinib

Formula: C₂₆H₂₇Cl₂FN₆O₃

Purity: 99.5%

Molecular weight: 561.44

Ref: 54-BUP21136

Ensartinib (X-396)

CAS: 1370651-20-9

Purity: 95%

Ref: IN-DA009IDP

Ensartinib(X-396)

CAS: 1370651-20-9

Formula: C₂₆H₂₇Cl₂FN₆O₃

Molecular weight: 561.44

Ref: 4Z-E-165001

Ensartinib

CAS: 1370651-20-9

Ensartinib (X-396) is a potent and orally active dual ALK/MET inhibitor for the treatment of ALK-positive non-small cell lung cancer (NSCLC).

Formula: C₂₆H₂₇Cl₂FN₆O₃

Purity: 99.92%

Color and Shape: Solid

Molecular weight: 561.44

Ref: TM-T37585

Ensartinib-13C2-d6

CAS: 1370651-20-9, 2137030-98-7

Formula: C₂₄₁₃C₂H₂₁D₆Cl₂FN₆O₃

Molecular weight: 569.46

Ref: 4Z-E-165002

Ensartinib

CAS: 1370651-20-9

Formula: C₂₆H₂₇Cl₂FN₆O₃

Molecular weight: 561.4

Ref: BE-RMCE071001

Ensartinib

CAS: 1370651-20-9

6-Amino-5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-N-(4-((3R,5S)-3,5-dimethylpiperazine-1-carbonyl)phenyl)pyridazine-3-carboxamide

Formula: C₂₆H₂₇Cl₂FN₆O₃

Purity: 98%

Molecular weight: 561.44

Ref: IN-DG00772696

Ensartinib

CAS: 1370651-20-9

Ensartinib is a small-molecule inhibitor of anaplastic lymphoma kinase (ALK), which is a receptor tyrosine kinase. This product is derived from chemical synthesis and classified as a targeted cancer therapy. Ensartinib’s mode of action involves the selective inhibition of ALK phosphorylation, which blocks downstream signaling pathways involved in cell proliferation and survival.

Formula: C₂₆H₂₇Cl₂FN₆O₃

Purity: Min. 95%

Molecular weight: 561.4 g/mol

Ref: 3D-VEC65120